Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
20 hedge funds and large institutions have $3.07M invested in Seelos Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
43% more funds holding
Funds holding: 14 → 20 (+6)
48% less capital invested
Capital invested by funds: $5.86M → $3.07M (-$2.78M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$771K |
| 2 |
Renaissance Technologies
New York
|
+$127K |
| 3 |
VF
Virtu Financial
New York
|
+$114K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$102K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$90.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$361K |
| 2 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$54.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 4 |
Squarepoint
New York
|
-$6.03K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$3K |
SEEL Hedge Fund Activity: Q3 2019 in Review
20 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2019, worth a combined $3.07M — down 48% from $5.86M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SEEL positions and 2 closed out — a net gain of 6 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $771K. The largest seller was Piper Sandler & Co, exiting entirely with an estimated $361K sold.
- 20 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2019, up from 14 in Q2 2019.
- Funds reported $3.07M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2019, down 48% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2019 and 2 closed out, a net change of +6 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2019 was Sabby Management, an estimated $771K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2019 was Piper Sandler & Co, an estimated $361K sold.
Based on aggregated 13F filings for Q3 2019.